Good day to you all.
Sirtuins are once again, making headlines. From a longer lifespan, again, through to helping old and dormant hair follicles to grow new hair, and of course a discourse between certain personalities on twitter, they continue to stimulate the interest and promise so much…
https://www.youtube.com/watch?v=pzVQ_R0BZaY
On July 20th, 2021 NASA’s Perseverance Mars Rover transmitted new images from Red Planet trying to collect first sample. Rover currently studying geological features of “Crater Floor Fractured Rough” area. While the rocks located in this geologic unit are not great time capsules for organics, NASA’s scientists believe they have been around since the formation of Jezero Crater and incredibly valuable to fill gaps in our geologic understanding of this region – things we’ll desperately need to know if we find life once existed on Mars. Photo of tube located in Mars rock was taken by Perseverance Rover on Sol 148.
Credit: nasa.gov, NASA/JPL-Caltech, NASA/JPL-Caltech/ASU
The University of Surrey has built an artificial intelligence (AI) model that identifies chemical compounds that promote healthy aging — paving the way towards pharmaceutical innovations that extend a person’s lifespan.
In a paper published by Nature Communication’s Scientific Reports, a team of chemists from Surrey built a machine learning model based on the information from the DrugAge database to predict whether a compound can extend the life of Caenorhabditis elegans — a translucent worm that shares a similar metabolism to humans. The worm’s shorter lifespan gave the researchers the opportunity to see the impact of the chemical compounds.
The AI singled out three compounds that have an 80 percent chance of increasing the lifespan of elegans:
Amazing.
While Venice may be home to the first 3D-printed concrete footbridge to be constructed entirely sans reinforcement or mortar, the similarly canal laced city of Amsterdam, not to be outdone, has unveiled the world’s first 3D-printed steel pedestrian bridge. The long-awaited project, first announced in 2015, was dedicated on the Oudezijds Achterburgwal canal in the city’s Red Light District on July 15. The ceremony was attended by Her Majesty the Queen of the Netherlands, Máxima, who was assisted by a ribbon-cutting robot during the festivities.
Spanning nearly 40 feet across the canal, the curving 6-ton stainless steel structure was constructed by Amsterdam-based 3D metal printing technology company MX3D using a wire arc additive manufacturing process that marries advanced robotics with welding. With the aid of four robots, the entire printing process took just six months. The completed bridge, designed by Joris Laarman Lab with Arup serving as lead engineer, was first unveiled in October 2018 during Dutch Design Week. Several load-testing rounds followed, the last of which was carried out in the fall of 2019 with plans to install the structure in early 2020. However, ongoing site prep work at the canal delayed the factory-produced bridge’s installation to just last week.
Continue reading “World’s first 3D-printed steel bridge debuts in Amsterdam’s Red Light District” »
Be it large enterprises or small medium-sized businesses, Quantum Computing and Artificial Intelligence (AI) are two of the biggest buzzwords in IT today.
Experiment connects three devices with entangled photons, demonstrating a key technique that could enable a future quantum internet. Experiment demonstrates a key technique that could enable a future quantum internet.
Stretchable electrodes are essential components for wearable electronics. However, the stretchability of the electrodes is often achieved with the sacrifice of electronic conductivity along with huge variation in resistance. In this work, stretchable metallic glass electrodes (MG-electrodes) that have both h.
Google’s parent Alphabet unveiled a new “moonshot” project to develop software for robotics which could be used in a wide range of industries.
The new unit, dubbed Intrinsic, will “become an independent Alphabet company,” and seek industrial partners to advance their work helping to make everything from solar panels to cars, the new unit’s chief, Wendy Tan-White, said in a blog post.
“Intrinsic is working to unlock the creative and economic potential of industrial robotics for millions more businesses, entrepreneurs, and developers,” she said.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019 and rapidly spread to other provinces in China as well as other countries. In this study, 262 patients diagnosed with moderate to severe SARS-CoV-2 pneumonia in Wuhan, China, were analyzed. Data were compared between survivors and nonsurvivors. Of all the 262 patients, 23 (8.8%) patients died and 239 (91.2%) were discharged. The median age was 63.5 years and 46.9% of patients were male. The main complaints were fever (83.6%), cough (63.4%), and fatigue (49.2%) in the surviving group, while there were more complaints of dyspnea (39.1%) and shortness of breath (56.5%) in the nonsurviving group. The main comorbidities were hypertension (35.5%), diabetes mellitus (16.4%), and coronary artery disease (9.9%). Morbidity is higher in elderly patients with more comorbidities. Patients were mainly treated with nasal cannula (93.9%), while the nonsurviving group received more invasive mechanical ventilation (39.1%). Arbidol (80.9%), ribavirin (36.6%), oseltamivir (38.9%), interferon (16.4%), and ganciclovir (14.5%) were used for the antiviral treatment. In the nonsurviving group, the number of white blood cells (WBC) was significantly increased and lymphocytes were decreased, and lymphopenia was more common. The levels of aspartate transaminase (AST), brain natriuretic peptide (BNP), creatine kinase isoenzyme MB (CK-MB), lactate dehydrogenase (LDH), and C-reactive protein (CRP) were also significantly increased in the nonsurviving group. The adjusted hazard ratios (HRs) for association of known variables for all-cause mortality due to the coronavirus disease 2019 were 2.467 (95% confidence interval[CI], 1.007−6.044; p = 0.048) for shortness of breath and 1.025 (95% CI, 1.001−1.049; p = 0.042) for AST. Elderly patients with more comorbidities and complaints of dyspnea and shortness of breath had increased risk of death. Patients with lymphopenia and high levels of WBC, AST, BNP, CK-MB, LDH, and CRP may be more likely to deteriorate.
Human Gene Therapy.
Tetra’s trial will be the first worldwide drug which involves the use of an injectable sterile synthetic cannabinoid in patients infected by COVID-19. Tetra will use this study to demonstrate that its ARDS-003 drug can help prevent the acute respiratory distress seen in serious complications of COVID-19.
The proposed study is a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of ARDS-003 in hospitalized COVID-19 patients with pneumonia and at risk of developing acute respiratory distress syndrome.
Seeking guidance on clinical study protocol to be conducted in patients with COVID-19 is a pre-requisite of the Health Canada regulatory process for COVID-related trials. The Office of Clinical Trials of Health Canada’s Therapeutic Products Directorate acknowledged that Tetra’s extensive nonclinical data, including genotoxicity, safety pharmacology and toxicities studies, assessing the safety and pharmacokinetic profile of the investigational drug meet the authority’s requirements for a New Molecular Entity and granted the Company the approval for filing a clinical trial application in patients infected with Sars-CoV-2 (COVID-19). The authorities also agreed on the proposed study design, target population, and primary and secondary objectives and endpoints of the study in severe COVID-19 patients. To this end, contingent to Health Canada’s accelerated review process for Covid-related trials, the Company’s drug ARDS-003, will be evaluated in COVID-19 patients.
Tetra’s trial will be the first worldwide drug which involves the use of an injectable sterile synthetic cannabinoid in patients infected by COVID-19. Tetra will use this study to demonstrate that its ARDS-003 drug can help prevent the acute respiratory distress seen in serious complications of COVID-19.
